Lexeo Therapeutics, Inc.
LXEO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001907108
In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $410.9M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Lexeo Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 60 | 1 | 69 | +10 |
| Shares | 26.6M | 791.6K | 29.7M | +3.95M (+15.3%) |
| Value | $426.3M | $12.7M | $268.8M | −$144.8M (−35.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Lexeo Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,630,287 | $14.7M | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,250,786 | $11.3M | 0.45% |
| Siren, L.L.C. | 603,435 | $5.46M | 0.27% |
| Point72 Asset Management, L.P. | 370,407 | $3.35M | 0.01% |
| Ikarian Capital, LLC | 257,216 | $2.33M | 0.72% |
| DAFNA Capital Management LLC | 250,583 | $2.27M | 0.54% |
| Perceptive Advisors LLC | 139,835 | $1.26M | 0.03% |
| Boothbay Fund Management, LLC | 107,484 | $971.7K | 0.03% |
| Exome Asset Management LLC | 88,148 | $796.9K | 0.54% |
| Prelude Capital Management, LLC | 30,725 | $277.8K | 0.02% |
| Jacobs Levy Equity Management, Inc | 30,346 | $274.3K | 0.00% |
| PDT Partners, LLC | 26,608 | $240.5K | 0.02% |
| Values First Advisors, Inc. | 7,446 | $67.3K | 0.04% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 174 | $1.57K | 0.00% |
| Steward Partners Investment Advisory, LLC | 100 | $904 | 0.00% |
| Sterling Capital Management LLC | 27 | $244 | 0.00% |
Sold out (6)
Institutions that held Lexeo Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 603,435 | $9.68M |
| Tudor Investment Corp Et Al | 132,187 | $2.12M |
| Franklin Resources Inc | 14,035 | $225.1K |
| EntryPoint Capital, LLC | 10,542 | $169.1K |
| Nisa Investment Advisors, LLC | 32 | $513 |
| GAMMA Investing LLC | 14 | $225 |
Not filed for Q3 2024 yet (1)
Institutions that held Lexeo Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 791,584 | $12.7M |